Recombinant idursulfase (JCR Pharmaceuticals/GlaxoSmithKline)

重组艾杜硫酯酶 (JCR Pharmaceuticals/GlaxoSmithKline)

Report date: 2025/05/06 15:48:39

Base Information

Drug NameRecombinant idursulfase (JCR Pharmaceuticals/GlaxoSmithKline)
Drug Alias Nameiduronate-2-sulfataserecombinant-iduronate-2-sulfataseGSK-2788723JR-032
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionIduronate-2-sulfatase replacements
TargetsIduronate-2-sulfatase
Therapy Area/IndicationsMucopolysaccharidosis II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJcr Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJcr Pharmaceuticals Co Ltd
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis II

Other Information

ATC CodeN/A
Related LinksN/A